MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of tumor cell proliferation compared with placebo plus Avastin as measured by the mean reduction in antigen KI-67 (MKI67; Ki-67) expression in a Phase 0 trial in 20 patients with HER2-negative breast cancer (29% vs. 9%, p=0.06). The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

MEI said the data are in line with preclinical data indicating the compound’s potential to reverse resistance to anti-angiogenic therapy. ME-344 was generally well tolerated in the open-label, Spanish trial, which was sponsored by Centro Nacional de Investigaciones Oncologicas...